Frontiers in Oncology | Hematologic Malignancies

Case Report

Published on 09 Dec 2021

Case Report: Graft Versus Tumor Effect After Non-Myeloablative Allogeneic Stem-Cell Transplantation in a Patient With Brentuximab-Vedotin Refractory Sezary Syndrome

in Hematologic Malignancies

Georg-Nikolaus Franke
Konstantin Dumann
Madlen Jentzsch
Astrid Monecke
Christine Doehring
Claudia Nehring-Vucinic
Sebastian Schwind
Dietger Niederwieser
Uwe Platzbecker
Mirjana Ziemer

Frontiers in Oncology

doi 10.3389/fonc.2021.749691

3,053 views
1 citation

Review

Published on 08 Dec 2021

Tumor Microenvironment of Lymphomas and Plasma Cell Neoplasms: Broad Overview and Impact on Evaluation for Immune Based Therapies

in Hematologic Malignancies

Sudhir Perincheri

Frontiers in Oncology

doi 10.3389/fonc.2021.719140

3,543 views
7 citations

Original Research

Published on 08 Dec 2021

Herbal NF-κB Inhibitors Sensitize Rituximab-Resistant B Lymphoma Cells to Complement-Mediated Cytolysis

in Hematologic Malignancies

Xiaowen Ge
Yiqun Du
Jianfeng Chen
Na Zhu
Jiamei Yao
Xin Zhang
Na Wang
Yujing Sun
Feng Gao
Weiguo Hu

Frontiers in Oncology

doi 10.3389/fonc.2021.751904

6,991 views
6 citations

Original Research

Published on 08 Dec 2021

Integration of a Geriatric Assessment With Intervention in the Care of Older Adults With Hematologic Malignancies

in Hematologic Malignancies

Sarah A. Wall
Ying Huang
Ashleigh Keiter
Allesia Funderburg
Colin Kloock
Nicholas Yuhasz
Tanya R. Gure
Edmund Folefac
Erin Stevens
Carolyn J. Presley

Frontiers in Oncology

doi 10.3389/fonc.2021.775050

4,959 views
13 citations

Original Research

Published on 07 Dec 2021

Long-Term Mixed Chimerism After Ex Vivo/In Vivo T Cell-Depleted Allogeneic Hematopoietic Cell Transplantation in Patients With Myeloid Neoplasms

in Hematologic Malignancies

Leo Ruhnke
Friedrich Stölzel
Uta Oelschlägel
Malte von Bonin
Katja Sockel
Jan Moritz Middeke
Christoph Röllig
Korinna Jöhrens
Johannes Schetelig
Christian Thiede

Frontiers in Oncology

doi 10.3389/fonc.2021.776946

3,600 views
2 citations

Clinical Trial

Published on 06 Dec 2021

Venetoclax Shows Low Therapeutic Activity in BCL2-Positive Relapsed/Refractory Peripheral T-Cell Lymphoma: A Phase 2 Study of the Fondazione Italiana Linfomi

in Hematologic Malignancies

Laura Ballotta
Pier Luigi Zinzani
Stefano Pileri
Riccardo Bruna
Monica Tani
Beatrice Casadei
Valentina Tabanelli
Stefano Volpetti
Stefano Luminari
Paolo Corradini

Frontiers in Oncology

doi 10.3389/fonc.2021.789891

5,151 views
9 citations

Original Research

Published on 06 Dec 2021

High Expression of BCL11A Predicts Poor Prognosis for Childhood MLL-r ALL

in Hematologic Malignancies

Lu-Lu Wang
Dehong Yan
Xue Tang
Mengqi Zhang
Shilin Liu
Ying Wang
Min Zhang
Guichi Zhou
Tonghui Li
Feifei Jiang

Frontiers in Oncology

doi 10.3389/fonc.2021.755188

4,411 views
9 citations

Original Research

Published on 06 Dec 2021

Early Dynamics and Depth of Response in Multiple Myeloma Patients Treated With BCMA CAR-T Cells

in Hematologic Malignancies

Sandy W. Wong
Nina Shah
Guy Ledergor
Thomas Martin
Jeffrey Wolf
Amy M. Shui
Chiung-Yu Huang
Joaquin Martinez-Lopez

Frontiers in Oncology

doi 10.3389/fonc.2021.783703

6,456 views
11 citations

Original Research

Published on 06 Dec 2021

Clinical Features and Prognostic Risk Prediction of Non-Hodgkin Lymphoma-Associated Hemophagocytic Syndrome

in Hematologic Malignancies

Shuyan Yao
Zhili Jin
Lingbo He
Ruoxi Zhang
Menghan Liu
Zhengjie Hua
Zhao Wang
Yini Wang

Frontiers in Oncology

doi 10.3389/fonc.2021.788056

4,742 views
19 citations

Original Research

Published on 03 Dec 2021

Preclinical Evaluation of the HDAC Inhibitor Chidamide in Transformed Follicular Lymphoma

in Hematologic Malignancies

Mengya Zhong
Jinshui Tan
Guangchao Pan
Yuelong Jiang
Hui Zhou
Qian Lai
Qinwei Chen
Liyuan Fan
Manman Deng
Bing Xu

Frontiers in Oncology

doi 10.3389/fonc.2021.780118

6,285 views
8 citations

Review

Published on 02 Dec 2021

Why Single-Cell Sequencing Has Promise in MDS

in Hematologic Malignancies

Xuan Zhang
H. Leighton Grimes

Frontiers in Oncology

doi 10.3389/fonc.2021.769753

7,358 views
4 citations

Systematic Review

Published on 02 Dec 2021

Efficacy and Safety of Lenalidomide Monotherapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma: Systematic Review and Meta-Analysis

in Hematologic Malignancies

Jia Li
Jianpeng Zhou
Wei Guo
Xingtong Wang
Yangzhi Zhao
Ou Bai

Frontiers in Oncology

doi 10.3389/fonc.2021.756728

4,346 views
4 citations

Original Research

Published on 02 Dec 2021

Impact of Cell-of-Origin on Outcome of Patients With Diffuse Large B-Cell Lymphoma Treated With Uniform R-CHOP Protocol: A Single-Center Retrospective Analysis From North India

in Hematologic Malignancies

Ajay Gogia
Sukesh Nair
Shalabh Arora
Lalit Kumar
Atul Sharma
Ritu Gupta
Ahitagni Biswas
Saumyaranjan Mallick

Frontiers in Oncology

doi 10.3389/fonc.2021.770747

4,014 views
9 citations

Original Research

Published on 01 Dec 2021

Selinexor Enhances NK Cell Activation Against Malignant B Cells via Downregulation of HLA-E

in Hematologic Malignancies

Jack G. Fisher
Christopher J. Walker
Amber DP. Doyle
Peter WM. Johnson
Francesco Forconi
Mark S. Cragg
Yosef Landesman
Salim. I. Khakoo
Matthew D. Blunt

Frontiers in Oncology

doi 10.3389/fonc.2021.785635

8,100 views
21 citations

Original Research

Published on 01 Dec 2021

Preclinical Evaluation of a Novel Dual Targeting PI3Kδ/BRD4 Inhibitor, SF2535, in B-Cell Acute Lymphoblastic Leukemia

in Hematologic Malignancies

Yongsheng Ruan
Hye Na Kim
Heather A. Ogana
Zesheng Wan
Samantha Hurwitz
Cydney Nichols
Nour Abdel-Azim
Ariana Coba
Seyoung Seo
Yong-Hwee Eddie Loh

Frontiers in Oncology

doi 10.3389/fonc.2021.766888

5,433 views
2 citations

Mini Review

Published on 29 Nov 2021

Biology and Treatment of High-Risk CLL: Significance of Complex Karyotype

in Hematologic Malignancies

Thomas Chatzikonstantinou
Christos Demosthenous
Panagiotis Baliakas

Frontiers in Oncology

doi 10.3389/fonc.2021.788761

4,939 views
9 citations

Review

Published on 29 Nov 2021

Early T-Cell Precursor Acute Lymphoblastic Leukemia: Diagnosis, Updates in Molecular Pathogenesis, Management, and Novel Therapies

in Hematologic Malignancies

Chun-fung Sin
Pui-hei Marcus Man

Frontiers in Oncology

doi 10.3389/fonc.2021.750789

50,489 views
53 citations

Mini Review

Published on 26 Nov 2021

Chromothripsis in Chronic Lymphocytic Leukemia: A Driving Force of Genome Instability

in Hematologic Malignancies

Kristyna Zavacka
Karla Plevova

Frontiers in Oncology

doi 10.3389/fonc.2021.771664

5,265 views
11 citations

Brief Research Report

Published on 25 Nov 2021

An Abnormal Host/Microbiomes Signature of Plasma-Derived Extracellular Vesicles Is Associated to Polycythemia Vera

in Hematologic Malignancies

Monica Barone
Martina Barone
Francesca Ricci
Giuseppe Auteri
Giulia Corradi
Francesco Fabbri
Valentina Papa
Erika Bandini
Giovanna Cenacchi
Pier Luigi Tazzari

Frontiers in Oncology

doi 10.3389/fonc.2021.715217

4,516 views
9 citations

Systematic Review

Published on 23 Nov 2021

Are the Derived Indexes of Peripheral Whole Blood Cell Counts (NLR, PLR, LMR/MLR) Clinically Significant Prognostic Biomarkers in Multiple Myeloma? A Systematic Review And Meta-Analysis

in Hematologic Malignancies

Xinwen Zhang
Jialin Duan
Zhenyu Wen
Hao Xiong
Xiaomin Chen
Yang Liu
Kunyu Liao
Chunlan Huang

Frontiers in Oncology

doi 10.3389/fonc.2021.766672

5,814 views
25 citations

Review

Published on 23 Nov 2021

Current Knowledge in Genetics, Molecular Diagnostic Tools, and Treatments for Mantle Cell Lymphomas

in Hematologic Malignancies

Shenon Sethi
Zachary Epstein-Peterson
Anita Kumar
Caleb Ho

Frontiers in Oncology

doi 10.3389/fonc.2021.739441

10,627 views
12 citations

Mini Review

Published on 19 Nov 2021

Advanced Pathogenetic Concepts in T-Cell Prolymphocytic Leukemia and Their Translational Impact

in Hematologic Malignancies

Till Braun
Annika Dechow
Gregor Friedrich
Michael Seifert
Johanna Stachelscheid
Marco Herling

Frontiers in Oncology

doi 10.3389/fonc.2021.775363

7,594 views
17 citations

Review

Published on 17 Nov 2021

Atypical Chronic Myelogenous Leukemia, BCR-ABL1 Negative: Diagnostic Criteria and Treatment Approaches

in Hematologic Malignancies

Panagiotis T. Diamantopoulos
Nora-Athina Viniou

Frontiers in Oncology

doi 10.3389/fonc.2021.722507

10,710 views
4 citations

Original Research

Published on 17 Nov 2021

Successful BCMA CAR-T Therapy for Multiple Myeloma With Central Nervous System Involvement Manifesting as Cauda Equina Syndrome—A Wandering Road to Remission

in Hematologic Malignancies

Yiyun Wang
Linqin Wang
Yifan Zeng
Ruimin Hong
Cheng Zu
Elaine Tan Su Yin
Houli Zhao
Guoqing Wei
Li Yang
Aiyun Jin

Frontiers in Oncology

doi 10.3389/fonc.2021.755584

5,970 views
11 citations

2,071 articles

articles

Case Report: Graft Versus Tumor Effect After Non-Myeloablative Allogeneic Stem-Cell Transplantation in a Patient With Brentuximab-Vedotin Refractory Sezary Syndrome

Tumor Microenvironment of Lymphomas and Plasma Cell Neoplasms: Broad Overview and Impact on Evaluation for Immune Based Therapies

Herbal NF-κB Inhibitors Sensitize Rituximab-Resistant B Lymphoma Cells to Complement-Mediated Cytolysis

Integration of a Geriatric Assessment With Intervention in the Care of Older Adults With Hematologic Malignancies

Long-Term Mixed Chimerism After Ex Vivo/In Vivo T Cell-Depleted Allogeneic Hematopoietic Cell Transplantation in Patients With Myeloid Neoplasms

Venetoclax Shows Low Therapeutic Activity in BCL2-Positive Relapsed/Refractory Peripheral T-Cell Lymphoma: A Phase 2 Study of the Fondazione Italiana Linfomi

High Expression of BCL11A Predicts Poor Prognosis for Childhood MLL-r ALL

Early Dynamics and Depth of Response in Multiple Myeloma Patients Treated With BCMA CAR-T Cells

Clinical Features and Prognostic Risk Prediction of Non-Hodgkin Lymphoma-Associated Hemophagocytic Syndrome

Preclinical Evaluation of the HDAC Inhibitor Chidamide in Transformed Follicular Lymphoma

Why Single-Cell Sequencing Has Promise in MDS

Efficacy and Safety of Lenalidomide Monotherapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma: Systematic Review and Meta-Analysis

Impact of Cell-of-Origin on Outcome of Patients With Diffuse Large B-Cell Lymphoma Treated With Uniform R-CHOP Protocol: A Single-Center Retrospective Analysis From North India

Selinexor Enhances NK Cell Activation Against Malignant B Cells via Downregulation of HLA-E

Preclinical Evaluation of a Novel Dual Targeting PI3Kδ/BRD4 Inhibitor, SF2535, in B-Cell Acute Lymphoblastic Leukemia

Biology and Treatment of High-Risk CLL: Significance of Complex Karyotype

Early T-Cell Precursor Acute Lymphoblastic Leukemia: Diagnosis, Updates in Molecular Pathogenesis, Management, and Novel Therapies

Chromothripsis in Chronic Lymphocytic Leukemia: A Driving Force of Genome Instability

An Abnormal Host/Microbiomes Signature of Plasma-Derived Extracellular Vesicles Is Associated to Polycythemia Vera

Are the Derived Indexes of Peripheral Whole Blood Cell Counts (NLR, PLR, LMR/MLR) Clinically Significant Prognostic Biomarkers in Multiple Myeloma? A Systematic Review And Meta-Analysis

Current Knowledge in Genetics, Molecular Diagnostic Tools, and Treatments for Mantle Cell Lymphomas

Advanced Pathogenetic Concepts in T-Cell Prolymphocytic Leukemia and Their Translational Impact

Atypical Chronic Myelogenous Leukemia, BCR-ABL1 Negative: Diagnostic Criteria and Treatment Approaches

Successful BCMA CAR-T Therapy for Multiple Myeloma With Central Nervous System Involvement Manifesting as Cauda Equina Syndrome—A Wandering Road to Remission